UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934
For the Month of June 2026
001-36203
(Commission File Number)
CAN-FITE BIOPHARMA LTD.
(Exact name of Registrant as specified in its charter)
26 Ben Gurion Street
Ramat Gan 5257346 Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒
Form 40-F ☐
The first three paragraphs of the press release
attached hereto as Exhibit 99.1 are hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File
No. 333-227753, 333-271384 and 333-278525)
and Form F-3 (File Nos. 333-236064, 333-276000, 333-274316, 333-281872, 333-262055,
and 333-294760), to be
a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed
or furnished.
On June 26, 2026, Can-Fite BioPharma Ltd. issued
a press release entitled “Can-Fite Secures Japanese Patent Allowance for Namodenoson’s Anti-Obesity Technology”. A copy of
this press release is furnished herewith as Exhibit 99.1.
Exhibit
Index
| Exhibit No. |
|
Description |
| 99.1 |
|
Press Release dated June 26, 2026 |
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
| Date: June 26, 2026 |
By: |
/s/ Motti Farbstein |
| |
|
Motti Farbstein |
| |
|
Chief Executive Officer and
Chief Financial Officer |
Exhibit 99.1
Can-Fite Secures Japanese Patent Allowance for
Namodenoson’s Anti-Obesity Technology
The allowed Patent strengthens
protection in one of the world’s largest pharmaceutical markets and further supports
Namodenoson’s positioning in obesity and metabolic
diseases
Ramat Gan, Israel, June 26, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma
Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs
targeting oncological and inflammatory diseases, today announced that the Japan Patent Office has allowed Japanese Patent Application
No. 2025-049941, a divisional application of JP 2023-078136, titled “An A3 Adenosine Receptor Ligand for Use for Achieving a Fat
Loss Effect.”
The allowed patent covers the use of A3 adenosine
receptor (A3AR) agonists, including the Company’s lead drug candidate Namodenoson, for inducing fat loss and treating obesity and related
metabolic disorders.
The Japanese patent allowance represents another
significant milestone in Can-Fite’s expanding global intellectual property portfolio covering Namodenoson’s anti-obesity activity. The
Company has already secured patent protection for this technology in major jurisdictions including the United States, Canada, Australia
and Israel, further strengthening its worldwide exclusivity strategy for this promising therapeutic indication.
The growing patent
estate is supported by scientific evidence recently published in the peer-reviewed International Journal of Obesity (https://rdcu.be/e37sf
), demonstrating Namodenoson’s anti-obesity activity and providing independent scientific validation for
its novel mechanism of action.
The global obesity therapeutics market continues
to experience rapid expansion, driven by increasing disease prevalence and the commercial success of GLP-1 receptor agonists. Despite
this growth, currently available therapies are frequently associated with gastrointestinal side effects, injectable administration, treatment
discontinuation, and high cost. Namodenoson, an orally administered, highly selective A3 adenosine receptor agonist with an established
safety profile from clinical studies, offers a differentiated mechanism of action by targeting key pathways involved in adipogenesis,
inflammation, and metabolic regulation. Preclinical and clinical findings suggest its potential to reduce fat accumulation while improving
metabolic parameters, positioning it as a promising candidate for future obesity therapy.
“The allowance of this patent in Japan significantly
strengthens our global intellectual property portfolio in one of the world’s most important pharmaceutical markets,” said Dr. Pnina
Fishman, Chairperson and Chief Scientific Officer of Can-Fite. “Together with our growing body of scientific evidence and established
clinical safety database, this expanding patent estate enhances the value of Namodenoson as a differentiated oral therapeutic candidate
for obesity and metabolic diseases and further supports future partnering opportunities.”
According to industry forecasts, the global obesity
therapeutics market is expected to exceed $60 billion by 2030, driven by increasing obesity prevalence and demand for safe, effective,
and convenient oral therapies.
About Namodenoson
Namodenoson is a small orally bioavailable drug
that binds with high affinity and selectivity to the A3 adenosine receptor (A3AR). Namodenoson is currently being evaluated in a pivotal
Phase 3 trial for advanced liver cancer, concluded successfully a Phase 2a study in pancreatic cancer and enrol patients for a Phase 2b
trial for the treatment of Metabolic Dysfunction-associated Steatohepatitis (MASH). A3AR is highly expressed in diseased cells whereas
low expression is found in normal cells. This differential expression may be one of the important factors that accounts for the excellent
safety profile of the drug.
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. (NYSE American: CANF)
(TASE: CANF) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion
dollar markets in the treatment of cancer, liver, and inflammatory disease. The Company’s lead drug candidate, Piclidenoson recently
reported topline results in a Phase 3 trial for psoriasis and commenced a pivotal Phase 3 trial. Can-Fite’s liver drug, Namodenoson,
is being evaluated in a Phase III trial for hepatocellular carcinoma (HCC), a Phase 2b trial for the treatment of MASH, and in a Phase
2a study in pancreatic cancer. Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation
as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially
treat other cancers including colon, prostate, and melanoma. CF602, the Company’s third drug candidate, has shown efficacy in the
treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,600 patients in clinical studies
to date. For more information please visit: www.canfite.com.
Forward-Looking Statements
This press release may contain forward-looking
statements, about Can-Fite’s expectations, beliefs or intentions regarding, among other things, its product development efforts.
All statements in this communication, other than those relating to historical facts, are “forward looking statements”. Forward-looking
statements can be identified by the use of forward-looking words such as “believe,” “expect,” “intend,”
“plan,” “may,” “should” or “anticipate” or their negatives or other variations of these
words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. Forward-looking
statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking
statements relate to matters that have not yet occurred, these statements are inherently subject to known and unknown risks, uncertainties
and other factors that may cause Can-Fite’s actual results, performance or achievements to be materially different from any future
results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual
results, performance or achievements to differ materially from those anticipated in these forward-looking statements include, among other
things, our market and other conditions, history of losses and needs for additional capital to fund our operations and our inability to
obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the
initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts;
our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials;
our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical
development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships
and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates;
the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our
ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and
our industry; risks related to not satisfying the continued listing requirements of NYSE American; and statements as to the impact of
the political and security situation in Israel on our business. More information on these risks, uncertainties and other factors is included
from time to time in the “Risk Factors” section of Can-Fite’s Annual Report on Form 20-F filed with the SEC on March
26, 2026 and other public reports filed with the SEC and in its periodic filings with the TASE. Existing and prospective investors are
cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Can-Fite undertakes
no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments
or otherwise, except as may be required by any applicable securities laws.
Contact
Can-Fite BioPharma
Motti Farbstein
info@canfite.com
+972-3-9241114
